The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity lasts. Current guidelines recommend vaccination of recovered patients even though data regarding vaccine effectiveness in such cases are still limited.

Matéria original


Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection


Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19